Expand NPCE Menu
NPCE MENU

NPCE Stock Posts


NPCE #Neuropace stock declines -10.5% in after hours trading. See the latest news.

After Hours Decliner

NPCE Neuropace15.31+0.01+0.1%

After Hours:13.70-1.61 (-10.5%)

NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy

Business WireTue, 28-Jul 4:01 PM
NPCE #Neuropace stock declines -10.5% in after hours trading. See the latest news.

After Hours Decliner

NPCE Neuropace15.31+0.01+0.1%

After Hours:13.70-1.61 (-10.5%)

NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy

Business WireTue, 28-Jul 4:01 PM
Upcoming Earnings

NPCE Neuropace15.66-0.01 (-0.1%)

Neuropace will report earnings after the market closes. View Calendar The market is expecting a ±6.4% move after earnings are reported. The average move for the past 4 quarters of earnings has been ±11.4%. View Expected Move (Conf Call: May 12 4:30 PM)
Upcoming Earnings

NPCE Neuropace13.71-0.44 (-3.1%)

Neuropace will report earnings after the market closes. View Calendar The market is expecting a ±10.3% move after earnings are reported. The average move for the past 4 quarters of earnings has been ±16.3%. View Expected Move (Conf Call: Mar 3 4:30 PM)
NPCE #Neuropace stock increases 21.4% after hours.

After Hours Gainer

NPCE Neuropace9.400.000.0%

After Hours:11.41+2.01 (+21.4%)

NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Business WireTue, 4-Nov 4:05 PM
NPCE #Neuropace stock increases 26.2% after hours.

After Hours Gainer

NPCE Neuropace9.400.000.0%

After Hours:11.86+2.46 (+26.2%)

NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Business WireTue, 4-Nov 4:05 PM
Load Earlier Posts
Market Data Delayed 15 Minutes